What is the Lincoln Pharmaceuticals PE ratio today?
Lincoln Pharmaceuticals' PE ratio is 10.5 at the 29 October 2026 close (₹509.90 a share): a market capitalisation of ₹1,021 crore divided by consolidated net profit of ₹96.9 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹87.9 crore) it is 11.6.
What is the Lincoln Pharmaceuticals net worth?
Lincoln Pharmaceuticals' net worth — shareholders' equity in its consolidated balance sheet — was ₹812 crore on 30 September 2026, up 13.4% from ₹716 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,021 crore at the 29 October 2026 close.
What is the Lincoln Pharmaceuticals book value per share?
Lincoln Pharmaceuticals' book value per share was ₹405.16 on 30 September 2026: shareholders' equity of ₹812 crore divided by the 2 crore shares in issue, up 13.4% from ₹357.35 a year earlier. The share price at the 29 October 2026 close was ₹509.90.
What is the Lincoln Pharmaceuticals PB ratio (price to book value)?
Lincoln Pharmaceuticals' price-to-book (PB) ratio is 1.26 at the 29 October 2026 close: a market capitalisation of ₹1,021 crore divided by shareholders' equity (book value) of ₹812 crore on 30 September 2026. That is a book value of ₹405.16 per share against a share price of ₹509.90.
What is the Lincoln Pharmaceuticals ROE and ROCE?
In FY26, Lincoln Pharmaceuticals' return on equity (ROE) was 12.3% and its return on capital employed (ROCE) was 11.3%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 13.0% and ROCE 13.6%.
What is the Lincoln Pharmaceuticals dividend yield?
Lincoln Pharmaceuticals' dividend yield is 0.35% at the 29 October 2026 close: dividends of ₹1.80 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹509.90. They were ₹1.80 on 11 September 2026.
What is the Lincoln Pharmaceuticals market cap?
Lincoln Pharmaceuticals' market capitalisation was ₹1,021 crore at the 29 October 2026 close: 2 crore shares at ₹509.90 each.
Is Lincoln Pharmaceuticals debt free?
No. Lincoln Pharmaceuticals had borrowings of ₹3.4 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.00. Its cash and current investments were ₹277 crore, so it held net cash of ₹273 crore.
What is the Lincoln Pharmaceuticals EPS?
Lincoln Pharmaceuticals' basic earnings per share (EPS) were ₹43.88 in FY26, against ₹41.11 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹48.38.
What is the Lincoln Pharmaceuticals debt to equity ratio?
Lincoln Pharmaceuticals' debt-to-equity ratio was 0.00 on 30 September 2026: borrowings of ₹3.4 crore against total equity of ₹812 crore. A year earlier, on 30 September 2025, it was 0.00.
What is the Lincoln Pharmaceuticals promoter holding?
Promoters held 49.78% of Lincoln Pharmaceuticals on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the Lincoln Pharmaceuticals free cash flow?
In FY26, Lincoln Pharmaceuticals generated ₹106 crore of cash from operations and spent ₹26 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹80.3 crore. In FY25 it was ₹74 crore.
What is the Lincoln Pharmaceuticals dividend in 2026 and its record date?
In 2026, Lincoln Pharmaceuticals has declared one dividend: ₹1.80 with record date 11 September 2026.
What are the Lincoln Pharmaceuticals latest quarterly results?
Lincoln Pharmaceuticals' latest results are for Q2 FY27 (July–September 2026), filed on 29 October 2026: consolidated net profit ₹20.4 crore, up 2.2% from ₹20 crore in Q2 FY26; revenue from operations ₹191 crore, up 17.1% year on year.
What is the Lincoln Pharmaceuticals revenue and profit in FY26?
In FY26 (April 2025–March 2026), Lincoln Pharmaceuticals' consolidated net profit was ₹87.9 crore, up 6.7% from ₹82.3 crore in FY25, on revenue from operations of ₹671 crore (up 7.7%). Over three years, from FY23, net profit was up 20.6%.
What is the Lincoln Pharmaceuticals shareholding pattern?
On 30 September 2026, Lincoln Pharmaceuticals' shares were held by promoters 49.78%, foreign portfolio investors (FII/FPI) 4.55%, domestic institutions (DII) 0.02% (including mutual funds at 0.00%) and retail and other non-institutional investors 45.65%. Over the year, FII holding was down 0.17 percentage points from 4.72% and DII holding was up 0.01 percentage points from 0.01%.
When are the Lincoln Pharmaceuticals next results?
Lincoln Pharmaceuticals has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
Lincoln Pharmaceuticals vs Sigachi Industries: how do they compare?
In FY26, Lincoln Pharmaceuticals earned net profit of ₹87.9 crore on revenue of ₹671 crore, against ₹81.8 crore on ₹478 crore for Sigachi Industries. Lincoln Pharmaceuticals' operating margin was 12.4% (Sigachi Industries 7.6%) and its return on equity 12.3% (Sigachi Industries −14.6%). At the 29 October 2026 close, Lincoln Pharmaceuticals' market capitalisation was ₹1,021 crore against ₹1,016 crore for Sigachi Industries.
How does Lincoln Pharmaceuticals compare with its peers?
On FY26 consolidated figures, against Sigachi Industries, Themis Medicare and Bajaj Healthcare: Lincoln Pharmaceuticals' operating margin of 12.4% is the second highest of the four (Sigachi Industries 7.6%, Themis Medicare −2.9%, Bajaj Healthcare 12.7%; peer average 5.8%); its return on equity of 12.3% is the highest of the four (Sigachi Industries −14.6%, Themis Medicare 0.3%, Bajaj Healthcare 3.2%; peer average −3.7%); its revenue growth over three years of 9.6% a year is the second highest of the four (Sigachi Industries 16.5% a year, Themis Medicare −1.2% a year, Bajaj Healthcare −3.2% a year; peer average 4.1% a year).
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
